Proficio Capital Partners LLC Makes New $567,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Proficio Capital Partners LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 909 shares of the biopharmaceutical company’s stock, valued at approximately $567,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Orbimed Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $11,358,000. Lockheed Martin Investment Management Co. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $2,702,000. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. National Pension Service lifted its stake in Regeneron Pharmaceuticals by 29.8% in the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock worth $278,636,000 after acquiring an additional 82,853 shares during the period. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $10,472,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron announced completion of a Phase 1/2 study evaluating its cemiplimab combination with SNS-101. The update keeps attention on potential pipeline progress, although the reports did not provide efficacy results or a regulatory timeline. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: A market analysis projects long-term growth in the complement-inhibitors market and lists Regeneron among leading participants. This is a broad industry forecast rather than a company-specific catalyst. 2026 Complement Inhibitors Market Analysis Report
• Neutral Sentiment: Analysts remain moderately optimistic about Regeneron, and the stock has outperformed the broader healthcare sector. The company’s recent earnings beat and double-digit revenue growth also support sentiment, though these factors were not new disclosures in the latest reports. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
• Negative Sentiment: Multiple law firms—including Hagens Berman, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, Portnoy and SueWallSt—are publicizing the same securities class action and a September 14, 2026 lead-plaintiff deadline. The complaints allege Regeneron misrepresented the risks and clinical differentiation of the Phase 3 Fianlimab-Libtayo study, including slowing event accrual and a protocol amendment that allegedly increased the risk of missing the primary endpoint. The repeated notices heighten legal and reputational risk, although they do not represent separate lawsuits or establish wrongdoing. REGN Deadline Alert

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. Wells Fargo & Company raised their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. HSBC reduced their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Royal Bank Of Canada lifted their price target on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Fourteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $800.36.

Insiders Place Their Bets

In related news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,400 shares of company stock valued at $1,090,030. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 3.4%

REGN stock opened at $852.03 on Thursday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $729.93 and a 200 day moving average of $719.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $854.49. The stock has a market capitalization of $87.72 billion, a PE ratio of 21.06, a price-to-earnings-growth ratio of 1.61 and a beta of 0.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $12.81 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.